These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7587021)

  • 1. Cefotaxime for the 1990s.
    Lode H
    Diagn Microbiol Infect Dis; 1995; 22(1-2):1-3. PubMed ID: 7587021
    [No Abstract]   [Full Text] [Related]  

  • 2. Cefotaxime failure in pneumococcal meningitis caused by a susceptible isolate.
    Flórez C; Silva G; Martín E
    Pediatr Infect Dis J; 1996 Aug; 15(8):723-4. PubMed ID: 8858688
    [No Abstract]   [Full Text] [Related]  

  • 3. Failure of cefotaxime therapy in a child with shigellosis.
    Hoffman JA; Kim KS
    Pediatr Infect Dis J; 1996 Feb; 15(2):175-6. PubMed ID: 8822296
    [No Abstract]   [Full Text] [Related]  

  • 4. Cefotaxime use in pediatric infections.
    Dajani AS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):105-10. PubMed ID: 7587022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacteriologic outcome of children with cefotaxime- or ceftriaxone-susceptible and -nonsusceptible Streptococcus pneumoniae meningitis.
    Olivier C; Cohen R; Begué P; Floret D
    Pediatr Infect Dis J; 2000 Oct; 19(10):1015-7. PubMed ID: 11055609
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro and in vivo combinations of cefotaxime and minocycline against Aeromonas hydrophila.
    Ko WC; Lee HC; Chuang YC; Ten SH; Su CY; Wu JJ
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1281-3. PubMed ID: 11257047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cefotaxime: current status and future prospectives after 15 years of experience].
    García-Rodríguez JA; García Sánchez JE; García Sánchez E; Fresnadillo MJ
    Rev Clin Esp; 1996 Jul; 196 Suppl 2():67-73. PubMed ID: 9558621
    [No Abstract]   [Full Text] [Related]  

  • 8. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: a review.
    Jones RN
    Diagn Microbiol Infect Dis; 1995; 22(1-2):19-33. PubMed ID: 7587039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefotaxime in the treatment of staphylococcal infections. Comparison of in vitro and in vivo studies.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1995; 22(1-2):195-201. PubMed ID: 7587040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cefotaxime in the treatment of surgical infections.
    Wittmann DH
    Diagn Microbiol Infect Dis; 1995; 22(1-2):173-82. PubMed ID: 7587036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cephalosporins--cefotaxime 10 years later, a major drug with continued use.
    Neu HC
    Infection; 1991; 19 Suppl 6():S309-15. PubMed ID: 1791075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
    Brogden RN; Spencer CM
    Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic failure with high-dose cefotaxime in pneumococcal meningitis].
    Michaus ML; Pérez-Díaz L; de Pablos M; Lezaun MJ; López-Bayón J
    Enferm Infecc Microbiol Clin; 1997 May; 15(5):276-7. PubMed ID: 9376392
    [No Abstract]   [Full Text] [Related]  

  • 14. The in vitro activity of cefotaxime versus bacteria involved in selected infections of hospitalized patients outside of the intensive care unit.
    Doern GV
    Diagn Microbiol Infect Dis; 1995; 22(1-2):13-7. PubMed ID: 7587027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quaternary heterocyclylamino beta-lactams. IV. Comparison of the in vivo antibacterial activities of L-640,876, mecillinam, cefoxitin and cefotaxime.
    Celozzi E; Pelak BA; Stapley EO; Gadebusch HH
    J Antibiot (Tokyo); 1983 Jan; 36(1):64-9. PubMed ID: 6088459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical role of cefixime in community-acquired infections.
    Chemotherapy; 1998 Sep; 44 Suppl 1():35-8. PubMed ID: 9797423
    [No Abstract]   [Full Text] [Related]  

  • 17. Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response.
    Thornsberry C; Jones RN; Barry AL; Fuchs PC
    Rev Infect Dis; 1982; 4 Suppl():S316-24. PubMed ID: 6294780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to ceftriaxone and cefotaxime in non-typhoidal Salmonella enterica in England and Wales, 1998-99.
    Threlfall EJ; Skinner JA; Graham A; Ward LR; Smith HR
    J Antimicrob Chemother; 2000 Nov; 46(5):860-2. PubMed ID: 11062222
    [No Abstract]   [Full Text] [Related]  

  • 20. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial.
    Li JT; Lu Y; Hou J; Chen YF; Miao JZ; Jia YX; Hou J; Zhang XZ; Chen DK; Hu WZ; Li LJ; Liu DM; Wang Z; Wu J; Gu JM; Wang HL; Zhang YL; Sun L
    Clin Infect Dis; 1997 Mar; 24(3):498-505. PubMed ID: 9114206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.